Tariff Shockwave: IT and Pharma Stocks Sink, ₹5,000 Crore FII Exodus Rattles Dalal Street

The Indian stock markets experienced a sharp downturn recently, as concerns over the United States imposing higher tariffs on Indian exports took center stage, hitting crucial sectors like information technology and pharmaceuticals. This development has triggered significant foreign institutional investor (FII) sell-offs worth around ₹5,000 crore, compounding worries about economic growth and corporate earnings. The slide comes amid the sixth consecutive week of market losses, marking one of the longest downward streaks in recent years.

Key Highlights of the Market Decline:

On August 8, 2025, the benchmark BSE Sensex plunged nearly 765 points (0.95%) to close at 79,857, falling below the psychologically important 80,000 mark for the first time since early May.

The NSE Nifty 50 index also lost 233 points (0.95%) to finish at 24,363, continuing its weak run amid ongoing tariff tensions and foreign fund outflows.

Foreign institutional investors were net sellers, offloading shares worth nearly ₹5,000 crore on the day, adding to August’s cumulative sell-off which already exceeded ₹15,000 crore.

Domestic institutional investors emerged as buyers, injecting about ₹10,800 crore, attempting to stabilize markets despite the negative headline pressures.

Key laggards included Bharti Airtel, Tata Motors, Kotak Mahindra Bank, Axis Bank, and Reliance Industries, while sectors like IT and pharmaceuticals saw pronounced declines due to tariff concerns.

The U.S. administration, under President Trump, intensified tariff rates on Indian imports, raising fears of a 50% duty escalation on various goods including pharmaceutical ingredients and other manufacturing inputs.

Although pharmaceuticals enjoyed a temporary exemption from initial tariff hikes due to their essential nature, the looming threat of future tariff increases has unsettled investors, driving share prices down for industry leaders such as Sun Pharma and Dr. Reddy’s.

The IT sector, while not directly targeted by tariffs, faces expected delayed impacts as tariff-induced cost pressures on clients in affected sectors could reduce discretionary spending on IT services.

Analysts warn that these tariffs could dampen India’s export growth and drag overall GDP expansion, with Indian engineering exports alone expected to decline by $4-5 billion.

On the currency front, the Indian rupee weakened against the dollar amid the sell-off, stoking concerns over imported inflation and higher borrowing costs.

Global commodity prices like crude oil rose slightly, adding cost-related worries for energy-sensitive sectors within India.

Volatility indices rose as investor nervousness increased, with broad market breadth skewing negative as risk-off sentiment prevailed.

Market and Economic Implications:

The US tariffs represent a significant trade barrier to India’s $434 billion export engine, potentially shrinking demand in one of India’s largest overseas markets. Indian pharma companies, exporting over $8.7 billion worth of drugs to the US (accounting for more than 30% of India’s pharma exports), have been particularly vocal about the threat to their competitiveness and profitability. The pharmaceutical industry's capacity and global regulatory standards make it uniquely positioned but vulnerable to tariff shocks.

Similarly, the IT sector, a backbone of India’s export revenue, is bracing for indirect repercussions as tariff burdens on manufacturing and other US client industries may lead to budget cuts in technology spending and digital transformation projects.

In response, market experts recommend cautious trading strategies, emphasizing investment in high-quality, defensive sectors and awaiting clarity on ongoing trade negotiations before expecting a market rebound.

Government and Industry Reactions:

Industry bodies, including the Pharmaceuticals Export Promotion Council (Pharmexcil), have called for dialogue with US authorities emphasizing India’s critical role in global healthcare and warning against tariffs that would ultimately raise drug prices for American consumers.

On the government front, India is exploring multi-pronged strategies focused on boosting exports to diversified markets, promoting import substitution domestically, and enhancing infrastructure resilience to mitigate tariff impact risks.

The market slide highlights the broader geopolitical risks that Indian investors must navigate amidst trade frictions, currency volatility, and global economic uncertainties as the country approaches a critical phase in growth and development.

Source: Economic Times, The Hindu Business Line, Times of India, Business Standard, Moneycontrol, Reuters